TrialInternational urogynecology journal2018

A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study).

David Staskin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.